"The
Report PharmaPoint: Prostate Cancer - Global Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Prostate
cancer is the second most common cancer in men worldwide, after skin
cancer. It accounts for 15% of all the cancers diagnosed in men, and
thus represents a huge burden on healthcare systems. While patients
diagnosed with early-stage, localized prostate cancer can be cured,
patients who are diagnosed with or progress to castration-resistant
prostate cancer (CRPC) have no curative options. This report focuses
on the current treatment landscape, unmet needs, pipeline assessment
and market outlook for prostate cancer. Since 2010, five new drugs
have been approved for the treatment of CRPC: Dendreons Provenge,
Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas
Xtandi, and Bayers Xofigo. During the forecast period from 2013-2023,
GlobalData expects that nine new late-stage pipeline agents will
launch, eight of which will be for the treatment of CRPC. As a result
of this unprecedented level of clinical development, GlobalData
predicts there will be massive changes in the CRPC treatment
paradigm. In addition, due to the influx of new therapies, the size
of the prostate cancer market across the nine major pharmaceutical
markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil,
and Canada) will increase three-fold.
View Report At
:http://www.marketresearchreports.biz/analysis/295880
Highlights
Key Questions Answered
-
How will prostate cancer disease management change as new agents
enter the market?
-
Which prostate cancer patients have the greatest unmet needs and how
well will these needs be addressed by the new agents?
-
What are the most dominant players in the prostate cancer space and
what corporate strategies are pursued by these companies?
-
What are the most promising late-stage pipeline agents for prostate
cancer? How do they compare to currently marketed products?
-
What opportunities will remain for future players following the
launch of these pipeline agents?
Key Findings
-
The prostate cancer market, in the 9MM is forecasted to rapidly
increase from $2.6bn in 2013 to $8.3bn in 2023, at a CAGR of 12.4%.
This growth will be driven by the label extensions of currently
marketed drugs as well as the launch of nine new premium-priced
therapies for the treatment of prostate cancer.
-
GlobalData expects Medivation and Astellas Xtandi will become the
market leader in prostate cancer. Xtandi is currently approved for
pre- and post-chemotherapy metastatic castration-resistant prostate
cancer (CRPC). Over the course of the forecast period, GlobalData
anticipates it will receive label extensions in non-metastatic CRPC
and hormone-sensitive prostate cancer, making it available to
virtually all prostate cancer patients segments, with the exception
of those with localized disease.
-
The prostate cancer pipeline is robust with nine drugs in late-stage
development. While androgen biosynthesis is still a major target,
many of the pipeline candidates have diverse mechanisms of action and
target proteins and pathways that are not targeted by the currently
marketed prostate cancer treatments. Among these new candidates are a
checkpoint inhibitor, a clusterin inhibitor, and an anti-angiogenic
agent. There are also several vaccines, both autologous and
off-the-shelf, that have a significant presence in this pipeline.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/295880
Scope
-
Overview of prostate cancer, including epidemiology, etiology,
pathophysiology, clinical staging, symptoms, prognosis, quality of
life, and disease management.
-
Annualized prostate cancer therapeutics market revenue from
2013-2023. Annual cost of therapy, and major marketed and pipeline
drug sales in this forecast period are included.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, and implications for the prostate
cancer therapeutics market.
-
Pipeline analysis: The prostate cancer pipeline is robust with many
late-stage candidates set to launch in the forecast period.
Comprehensive analysis of the nine most promising candidates in Phase
III development are highlighted and profiled.
-
Analysis of the current and future market competition in the global
prostate cancer therapeutics market, including insightful review of
the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline.
-
Develop business strategies by understanding the trends shaping and
driving the 9MM prostate cancer market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
9MM prostate cancer therapeutics market in the future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and
Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 24
3.2 Staging 25
3.3 Symptoms 29
3.4 Prognosis 29
3.5 Quality of Life 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and
Comorbidities 31
4.3 Global Trends 34
4.3.1 US 35
4.3.2 5EU 36
4.3.3 Japan, Brazil, and Canada
36
4.4 Forecast Methodology 37
4.4.1 Sources Used 38
4.4.2 Sources Not Used 44
4.4.3 Forecast Assumptions and
Methods 45
4.5 Epidemiological Forecast
for Prostate Cancer (2013-2023) 48
4.5.1 Diagnosed Incident Cases
of Prostate Cancer 48
4.5.2 Age-Specific Diagnosed
Incident Cases of Prostate Cancer 50
4.5.3 Age-Standardized
Diagnosed Incidence of Prostate Cancer 52
4.5.4 Clinical Stage at
Diagnosis 54
4.5.5 Diagnosed Five-Year
Prevalent Cases of Prostate Cancer 55
4.5.6 Diagnosed Five-Year
Prevalent Cases of CRPC 56
4.5.7 Diagnosed Five-Year
Prevalent Cases of Bone Metastases Among CRPC Patients 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast
Insight 60
4.6.2 Limitations of the
Analysis 61
4.6.3 Strengths of the Analysis
62
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment